283 related articles for article (PubMed ID: 31708481)
1. Hepatitis B virus seroprevalence among HIV-infected patients receiving combination antiretroviral therapy three decades after universal neonatal hepatitis B immunization program in Taiwan.
Lin JJ; Lin KY; Tang HJ; Lin SP; Lee YC; Liu CE; Huang YS; Wang NC; Li CW; Ko WC; Yang HJ; Lee YT; Hung CC;
J Microbiol Immunol Infect; 2021 Apr; 54(2):228-237. PubMed ID: 31708481
[TBL] [Abstract][Full Text] [Related]
2. Seroprevalence of hepatitis B virus among adults at high risk for HIV transmission two decades after implementation of nationwide hepatitis B virus vaccination program in Taiwan.
Sun HY; Cheng CY; Lee NY; Yang CJ; Liang SH; Tsai MS; Ko WC; Liu WC; Wu PY; Wu CH; Lin HH; Hung CC
PLoS One; 2014; 9(2):e90194. PubMed ID: 24587275
[TBL] [Abstract][Full Text] [Related]
3. Virological Response to Tenofovir Disoproxil Fumarate in HIV-Positive Patients with Lamivudine-Resistant Hepatitis B Virus Coinfection in an Area Hyperendemic for Hepatitis B Virus Infection.
Huang YS; Chang SY; Sheng WH; Sun HY; Lee KY; Chuang YC; Su YC; Liu WC; Hung CC; Chang SC
PLoS One; 2016; 11(12):e0169228. PubMed ID: 28033344
[TBL] [Abstract][Full Text] [Related]
4. Five-year on-treatment efficacy of lamivudine-, tenofovir- and tenofovir + emtricitabine-based HAART in HBV-HIV-coinfected patients.
Kosi L; Reiberger T; Payer BA; Grabmeier-Pfistershammer K; Strassl R; Rieger A; Peck-Radosavljevic M
J Viral Hepat; 2012 Nov; 19(11):801-10. PubMed ID: 23043387
[TBL] [Abstract][Full Text] [Related]
5. Impact of antiretroviral therapy containing tenofovir disoproxil fumarate on the survival of patients with HBV and HIV coinfection.
Tsai WC; Hsu WT; Liu WD; Sun HY; Chuang YC; Huang YS; Cheng A; Lin KY; Huang YC; Chen GJ; Huang SH; Sheng WH; Hsieh SM; Hung CC; Chang SC
Liver Int; 2019 Aug; 39(8):1408-1417. PubMed ID: 30712284
[TBL] [Abstract][Full Text] [Related]
6. Long-term virological and serologic responses of chronic hepatitis B virus infection to tenofovir disoproxil fumarate-containing regimens in patients with HIV and hepatitis B coinfection.
Huang YS; Sun HY; Chang SY; Chuang YC; Cheng A; Huang SH; Huang YC; Chen GJ; Lin KY; Su YC; Liu WC; Hung CC
Hepatol Int; 2019 Jul; 13(4):431-439. PubMed ID: 31177505
[TBL] [Abstract][Full Text] [Related]
7. Serological responses to revaccination against HBV in HIV-positive patients born in the era of nationwide neonatal HBV vaccination.
Huang YC; Hsieh SM; Sheng WH; Huang YS; Lin KY; Chen GJ; Yang SP; Liu WC; Su YC; Sun HY; Hung CC; Chang SC
Liver Int; 2018 Nov; 38(11):1920-1929. PubMed ID: 29446249
[TBL] [Abstract][Full Text] [Related]
8. Lamivudine Monotherapy-Based cART Is Efficacious for HBV Treatment in HIV/HBV Coinfection When Baseline HBV DNA <20,000 IU/mL.
Li Y; Xie J; Han Y; Wang H; Zhu T; Wang N; Lv W; Guo F; Qiu Z; Li Y; Du S; Song X; Thio CL; Li T
J Acquir Immune Defic Syndr; 2016 May; 72(1):39-45. PubMed ID: 26745828
[TBL] [Abstract][Full Text] [Related]
9. HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes.
Hamers RL; Zaaijer HL; Wallis CL; Siwale M; Ive P; Botes ME; Sigaloff KC; Hoepelman AI; Stevens WS; Rinke de Wit TF;
J Acquir Immune Defic Syndr; 2013 Oct; 64(2):174-82. PubMed ID: 23892239
[TBL] [Abstract][Full Text] [Related]
10. Seroprevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) among human immunodeficiency virus (HIV)-infected patients in an HBV endemic area in Brazil.
da Silva CM; de Peder LD; Guelere AM; Horvath JD; Silva ES; Teixeira JJV; Bertolini DA
PLoS One; 2018; 13(9):e0203272. PubMed ID: 30192795
[TBL] [Abstract][Full Text] [Related]
11. Lamivudine plus tenofovir versus lamivudine plus adefovir for the treatment of hepatitis B virus in HIV-coinfected patients, starting antiretroviral therapy.
Sarkar J; Saha D; Bandyopadhyay B; Saha B; Chakravarty R; Guha SK
Indian J Med Microbiol; 2018; 36(2):217-223. PubMed ID: 30084414
[TBL] [Abstract][Full Text] [Related]
12. Antenatal hepatitis B virus sero-prevalence, risk factors, pregnancy outcomes and vertical transmission rate within 24 months after birth in a high HIV prevalence setting.
Duri K; Munjoma PT; Mataramvura H; Mazhandu AJ; Chandiwana P; Marere T; Gumbo FZ; Mazengera LR
BMC Infect Dis; 2023 Oct; 23(1):736. PubMed ID: 37891471
[TBL] [Abstract][Full Text] [Related]
13. Uptake of tenofovir-based antiretroviral therapy among HIV-HBV-coinfected patients in the EuroSIDA study.
Peters L; Mocroft A; Grint D; Moreno S; Calmy A; Jevtovic D; Sambatakou H; Lacombe K; De Wit S; Rockstroh J; Smidt J; Karpov I; Grzeszczuk A; Haziosmanovic V; Gottfredsson M; Radoi R; Kuzovatova E; Orkin C; Ridolfo AL; Zapirain J; Lundgren J
Antivir Ther; 2018; 23(5):405-413. PubMed ID: 29303483
[TBL] [Abstract][Full Text] [Related]
14. Virological responses to tenofovir-alafenamide-containing antiretroviral therapy in people living with HIV co-infected with lamivudine-resistant or lamivudine-susceptible hepatitis B virus.
Huang YS; Sun HY; Chang SY; Chuang YC; Su YC; Liu WC; Hung CC
Int J Antimicrob Agents; 2022; 60(5-6):106682. PubMed ID: 36279976
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic effect of antiretroviral therapy on hepatitis B virus infection.
Gatanaga H; Hayashida T; Tanuma J; Oka S
Clin Infect Dis; 2013 Jun; 56(12):1812-9. PubMed ID: 23487374
[TBL] [Abstract][Full Text] [Related]
16. Emergence of Lamivudine-Resistant HBV during Antiretroviral Therapy Including Lamivudine for Patients Coinfected with HIV and HBV in China.
Gu L; Han Y; Li Y; Zhu T; Song X; Huang Y; Yang F; Guan S; Xie J; Gohda J; Hosoya N; Kawana-Tachikawa A; Liu W; Gao GF; Iwamoto A; Li T; Ishida T
PLoS One; 2015; 10(8):e0134539. PubMed ID: 26288093
[TBL] [Abstract][Full Text] [Related]
17. Combination HBV therapy is linked to greater HBV DNA suppression in a cohort of lamivudine-experienced HIV/HBV coinfected individuals.
Matthews GV; Seaberg E; Dore GJ; Bowden S; Lewin SR; Sasadeusz J; Marks P; Goodman Z; Philp FH; Tang Y; Locarnini S; Thio CL
AIDS; 2009 Aug; 23(13):1707-15. PubMed ID: 19584701
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B testing, treatment, and virologic suppression in HIV-infected patients in Cameroon (ANRS 12288 EVOLCAM).
Liégeois F; Boyer S; Eymard-Duvernay S; Carrieri P; Kouanfack C; Domyeum J; Maradan G; Ducos J; Mpoudi-Ngolé E; Spire B; Delaporte E; Kuaban C; Vidal L; Laurent C;
BMC Infect Dis; 2020 Jan; 20(1):49. PubMed ID: 31941464
[TBL] [Abstract][Full Text] [Related]
19. Role of a 48-week pegylated interferon therapy in hepatitis B e antigen positive HIV-co-infected patients on cART including tenofovir: EMVIPEG study.
Miailhes P; Maynard-Muet M; Lebossé F; Carrat F; Bouix C; Lascoux-Combe C; Sogni P; Rey D; Barthe Y; Pol S; Cacoub P; Zoulim F; Piroth L
J Hepatol; 2014 Oct; 61(4):761-9. PubMed ID: 24882048
[TBL] [Abstract][Full Text] [Related]
20. Seroprevalence of hepatitis virus infection in men who have sex with men aged 18-40 years in Taiwan.
Tseng YT; Sun HY; Chang SY; Wu CH; Liu WC; Wu PY; Lu CL; Hsieh CY; Hung CC
J Formos Med Assoc; 2012 Aug; 111(8):431-8. PubMed ID: 22939661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
